Literature DB >> 21428155

Effects of streamlining cervical cancer screening the Dutch way: consequences of changes in the Dutch KOPAC-based follow-up protocol and consensus-based limitation of equivocal cytology.

Martijn C Briët1, Thomas H D Berger, Marjolein van Ballegooijen, Mathilde E Boon, Matejka Rebolj.   

Abstract

OBJECTIVE: To analyze the impact of the 1995 revision of the Dutch cervical screening program guidelines (e.g., the introduction of more stringent criteria for cytologic diagnosis of atypical squamous cells of undetermined significance [ASCUS]) on the negative side effects of screening in Region West. STUDY
DESIGN: The data for this study were retrieved as two complementary datasets, both of which contained data on the invited screenees, including their cytology and histology follow-up. One dataset additionally included data on other smears. For invited screenees, we analyzed changes in cytoscores and histoscores between 1994, the last year before new screening guidelines were implemented, and 2003, the latest year for which follow-up to screening abnormalities was available in the retrieved data. Additionally, we analyzed changes in the total number of primary and repeat smears made.
RESULTS: Between 1994 and 2003, the cytoscore for ASCUS decreased from 19.4% to 1.3% of screenee smears. The total number of smears taken decreased by 30%. The cervical intraepithelial neoplasia 3+ histoscore remained the same (OR = 0.97, p = 0.91).
CONCLUSION: The reduction of equivocal ASCUS diagnoses resulted in a decrease of costly repeat smears, without measurably decreasing the effectiveness of the screening program.

Entities:  

Mesh:

Year:  2010        PMID: 21428155     DOI: 10.1159/000325251

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  1 in total

1.  Harms of cervical cancer screening in the United States and the Netherlands.

Authors:  Dik Habbema; Sheila Weinmann; Marc Arbyn; Aruna Kamineni; Andrew E Williams; Inge M C M de Kok; Folkert van Kemenade; Terry S Field; Joost van Rosmalen; Martin L Brown
Journal:  Int J Cancer       Date:  2017-03-01       Impact factor: 7.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.